Eisai Inc. announced results from the REFLECT study, a phase III trial evaluating lenvatinib (Lenvima), the company’s multiple receptor tyrosine kinase inhibitor (including fibroblast growth factor receptors, for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Marking a new era of non-invasive medical interventions, the Northwell Health Cancer Institute is investing $1.2 million in the development of cutting-edge histotripsy technology to treat some liver cancer tumors without surgery. This innovative approach uses targeted ultrasound beams to create microbubbles within tumors, effectively disrupting and destroying diseased cells without the need for incisions.
